Evidence map›Paper›PMID 29544344›Full record

ReviewThe British journal of radiology2019

The tumour microenvironment links complement system dysregulation and hypoxic signalling.

Monica M Olcina, Ryan K Kim, Stavros Melemenidis, Edward E Graves, Amato J Giaccia

Open access · hybridAbstract readReview
In one paragraph

Review in The British journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Frontiers in oncology · 2022
    Article
  8. Review
  9. Review
  10. Article
  11. Dexmedetomidine enhances hypoxia-induced cancer cell progression.Experimental and therapeutic medicine · 2019
    Article
  12. Article
  13. Hypoxia-Modified Cancer Cell Metabolism.Frontiers in cell and developmental biology · 2019
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Monica M OlcinaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9580-2169
Ryan K KimDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Stavros MelemenidisDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Edward E GravesDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Amato J GiacciaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Stanford University · US

Funding

TUMOR HYPOXIA--MOLECULAR STUDIES &CLINICAL EXPLOITATIONP01CA067166 · NCI · STANFORD UNIVERSITY · PI DENKO, NICHOLAS C. · 1996 to 2017
$25.5M
The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor GrowthR35CA197713 · NCI · STANFORD UNIVERSITY · PI GIACCIA, AMATO J. · 2015 to 2021
$5.3M
Small Animal Radiation Research Platform @ StanfordS10OD018208 · OD · STANFORD UNIVERSITY · PI GRAVES, EDWARD E. · 2014 to 2014
$600k
NCI NIH HHS P01 CA067166NCI NIH HHS R35 CA197713NIH HHS S10 OD018208
6 · The paper itself

Abstract

The complement system is an innate immune pathway typically thought of as part of the first line of defence against "non-self" species. In the context of cancer, complement has been described to have an active role in facilitating cancer-associated processes such as increased proliferation, angiogenesis and migration. Several cellular members of the tumour microenvironment express and/or produce complement proteins locally, including tumour cells. Dysregulation of the complement system has been reported in numerous tumours and increased expression of complement activation fragments in cancer patient specimens correlates with poor patient prognosis. Importantly, genetic or pharmacological targeting of complement has been shown to reduce tumour growth in several cancer preclinical models, suggesting that complement could be an attractive therapeutic target. Hypoxia (low oxygen) is frequently found in solid tumours and has a profound biological impact on cellular and non-cellular components of the tumour microenvironment. In this review, we focus on hypoxia since this is a prevailing feature of the tumour microenvironment that, like increased complement, is typically associated with poor prognosis. Furthermore, interesting links between hypoxia and complement have been recently proposed but never collectively reviewed. Here, we explore how hypoxia alters regulation of complement proteins in different cellular components of the tumour microenvironment, as well as the downstream biological consequences of this regulation.

Indexed as

Combined Modality TherapyComplement System ProteinsFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasmsOxygen ConsumptionPrognosisSignal TransductionTreatment OutcomeTumor HypoxiaTumor MicroenvironmentUp-RegulationComplement System Proteins

Identifiers

PMID29544344
PMCPMC6435069
OpenAlexW2793838319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.